Key Trends in the Asthma and COPD Market - Uncertain times for novel inhalation devices

Introduction:

Treatment of both asthma and COPD is largely palliative, and cross-indication of anti-asthmatic drugs for use in COPD is commonplace. However, efforts to target disease progression by identifying novel anti-inflammatory mediators are intensifying. This Brief investigates the role of product extensions through reformulations and cross indications, and of novel therapies and devices. 

Scope:

* Determine current asthma and COPD prevalence rates and future trends in the seven major markets 

* Analyze developments in the pulmonary device sector and determine the impact of liquid based inhalers 

* Identify the most promising novel therapies under investigation for both asthma and COPD, including monoclonal antibodies and PDE-4 inhibitors 

* Examine the factors that will determine the continued success of Advair, Singulair and why Spiriva will revolutionized the COPD market 

Report Highlights:

The prevalence of asthma is set to continue to increase, with Advair (fluticasone and salmeterol) and Singulair (montelukast) remaining at the forefront of treatment options. Spiriva (tiotropium), Ariflo (cilomilast) and roflumilast will breathe life into a rapidly expanding COPD market 

Improvements to pressurized metered dose inhalers (pMDIs) and dry powdered inhalers (DPIs) have incurred significant cost and given the paucity of NCEs, only a select number of delivery device companies will survive. The future of systemic delivery via the lung is uncertain, as it will be heavily dependent on the success of inhaled insulin 

Reasons to Purchase:

* Understand key developments in the pulmonary device sector 

* Appraise the key pipeline and marketed drugs in asthma and COPD treatment 

Publisher: Datamonitor Immune Disorders and Inflammation Rep. 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Immune_Disorders_and_Inflammation.html#a144